AI summary by TwinMind
Jaykumar Menon | Open Source Pharma and Respiratory Pandemics | Talks at Google
Talks at Google
44m 59s
Introduction & Background
- Jay Kumar Mainen introduced by Google Assistant team
- Chair and co-founder of Open Source Pharma Foundation (global non-profit)
- Human rights litigator background, senior fellow at Harvard Global Health Institute
- Visiting scientist at Harvard School of Public Health
- William Rogers Award recipient (Brown's alumnus of the year)
- Social activist involved in:
- Freeing wrongly convicted individuals (life sentence and death penalty cases)
- Addressing iron deficiency in India and Tanzania
Personal Journey to Open Source Pharma
- Previously worked at Center for Constitutional Rights (NYC)
- Two main case types: head of state and death row/murder cases
- Represented Tiananmen Square student leaders, Bosnian genocide victims
- Organization won cases in Guantanamo at Supreme Court
- Helped free David Wong as 15th lawyer on case
- Worked at X Prize Foundation on innovation models for social problems
- Focused on "giga scale social innovation" affecting 1+ billion people
- Transformative change through open innovation techniques
Salt Project (Iron Deficiency Solution)
- 2 billion people worldwide lack sufficient micronutrients (particularly iron)
- 5 billion people consume iodized salt daily
- Solution: Added iron to iodized salt
- Project scaled to 1+ billion meals
- Cost: 25 cents per person per year
- Expanding to more nutrients and geographies (Tanzania next)
Village Lab Video Presentation
- Professor from Kerala, India demonstrating remote research capabilities
- Students publishing international papers from basic facilities
- Internet enabling global knowledge access and collaboration
- Aisha's story: Conservative family background, developed home lab
- Passion for research enabled by internet connectivity
Open Source Pharma Foundation Overview
- Only 5% of human diseases have FDA-approved cures
- Current system oriented toward most lucrative diseases
- Exponentially declining productivity in pharma sector (Eroom's Law vs Moore's Law)
- Drug development costs: $2.5+ billion per drug
- Timeline: 12-17 years development time
- 95% of ailments lack approved cure/treatment
Open Source Model Application
- Drawing parallels to software industry (Android, Chrome, Mozilla, Linux)
- Leveraging billions of people not engaged in drug discovery process
- Three-step process:
- Early stages: Online/computer-based (easy for open source)
- Middle step: Wet labs (crowdsourcing, Airbnb-style networks)
- Final step: Generic drug industry infrastructure for distribution
Scientific Validation & Partnerships
- Significant papers published in Nature
- Government of India involvement
- 2014 Rockefeller Foundation conference
- Participants: Big pharma, small pharma, academia, NGOs, computer theorists
- Initial funding received in 2018
- Bangalore main office, presence in Paris and New York
- Goal: Cut costs by 90%+, time by 50%+
- "Linux for drugs" and "medicine for all" mottos
Tuberculosis Success Case
- 1/4 of humanity infected with TB bacteria
- Most widely used TB drug is 50 years old
- Repurposed diabetes drug metformin for tuberculosis
- Reached Phase 2b trials in first funded year
- Cost: Less than $50,000 (several orders of magnitude less than standard pharma)
- Late stage clinical trials with Government of India
COVID-19 Projects
Antibody Cocktail Project
- Based on DARPA technology (used by US President)
- Map, clone, mass produce antibodies from COVID survivors
- Global network for localized production
- Small biotechs/hospitals can produce on-site with no royalties
- Provides ~3 months immunity
Repurposing Hub
- Nearly every COVID drug in clinical trials is repurposed
- Lack of infrastructure for repurposing knowledge
- Partnership with US/Brazil governments, NIH, PhilCruz, EU-backed Actress group
- Creating global hub for open source approaches
Open Source Drug Discovery Software
- "Red Hat for medicines"
- Village lab community needs better software tools
- Current software is flawed
- Potential for wave-upon-wave innovation (similar to software industry)
Open Source COVID-19 Vaccine Development
- All-star cast of Harvard scientists backing concept
- Paul Farmer and Tachi Yamada (former R&D leader at Gates Foundation, GSK, Takeda)
- Repurposing old vaccines with open IP for COVID-19
Scientific Mechanism
- Live attenuated vaccines train innate immunity
- Provides broad umbrella protection beyond specific pathogen
- Published in New England Journal of Medicine
- 100+ years of known broad immunity effects
Real-World Evidence
- USS Roosevelt case study: 1,000 sailors COVID-positive, only 1 hospitalized
- Sailors receive MMR vaccine upon enlistment
- Cross-national studies showing infection rates vs vaccine rates
- BCG study: 45% reduction in all respiratory infections in elderly
Trial Details
- 100x cheaper to repurpose existing vaccine vs creating new one
- Phase 3 trials ready to launch
- Partners: Open Source Pharma Foundation, Harvard Medical School, Government of India
- US trial: Nursing homes and elderly population
- Manufacturing already in place, decades of safety data
- Vaccines cost as little as 11 cents per dose
Funding Requirements
- US trial: $3 million
- India trial: $400,000-$700,000
- Total package: $10 million for multiple candidates/trials
- Philanthropic model (no profit motive)
- Industry doesn't support this type of work
Q&A Session
Revaccination Requirements
- MMR and BCG vaccines wear off over time
- Need first-time vaccination or revaccination for protection
- Still being studied in trials
Implementation Challenges
- Clinical trials are logistically complex
- Shortage of epidemiologists and clinical trial specialists
- Most specialists booked with more remunerative projects
- Intellectual battle: Repurposing viewed as less prestigious
- Body is complex system, not simple mechanistic view
Legal Structures
- "Common heritage of all humankind" principle
- Open intellectual property - no monopolization possible
- Multiple producers can compete
- No hoarding possible
- Better economically due to competition
Contributor Incentives
- Similar to software open source model
- Learning opportunities and recognition
- Community participation
- Micro attributions on papers
- Training for young scientists
- Professors leverage larger teams
Trial Timeline
- BCG trial in India already launched (elderly patients)
- Second India trial: Ethics approvals in weeks
- US trial: Sites identified, may expand beyond nursing homes
- First patient enrollment: Matter of weeks after funding
